- Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Black Diamond Therapeutics Announces Changes to Board of Directors
- Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
- Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
- Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
- Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
- Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
- Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
- Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.67 |
---|---|
High | 7.14 |
Low | 6.60 |
Bid | 6.30 |
Offer | 6.95 |
Previous close | 6.59 |
Average volume | 816.83k |
---|---|
Shares outstanding | 52.53m |
Free float | 51.18m |
P/E (TTM) | -- |
Market cap | 346.17m USD |
EPS (TTM) | -1.92 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼